COPD 2005 - eine Übersicht

Einführung

Die chronisch obstruktive Lungenerkrankung (COPD) ist bereits heute eine Volkskrankheit mit weiter steigender Morbidität und Mortalität. Sie wird im Jahre 2020 weltweit die dritthäufigste Todesursache darstellen [1]. In Mitteleuropa beträgt die Prävalenz derzeit ca. 6 - 7,5 % [2]. Der Hauptrisikofaktor in den Industrieländern ist das Rauchen, gefolgt von berufsbedingten inhalativen Noxen.

Der Beitrag diskutiert neue Erkenntnisse aus der Pathophysiologie der Erkrankung sowie aktuelle Entwicklungen in der medikamentösen und multidisziplinären Therapie.

Literatur

• 1 Lopez A D, Murray C C. The global burden of disease, 1990 - 2020.  Nat Med. 1998;  11 1241-1243
• 2 European Respiratory Society .European Lung Whithe Book. Lausanne, Switzerland: European Respiratory Society 2003: 1-182
• 3 ATS/ERS Task Force . Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper.  Eur Respir J. 2004;  23 932-946
• 4 Worth H. Leitlinie der Deutschen Atemwegsliga und der Deutschen Gesellschaft für Pneumologie zur Diagnostik und Therapie von Patienten mit chronisch obstruktiver Bronchitis und Lungenemphysem.  Pneumologie. 2002;  56 703-737
• 5 Hogg J, Coxon H O, Pare P D. The nature of small-airway obstruction in chronic obstructive pulmonary disease.  N Engl J Med. 2004;  26 2645-2653
• 6 Barnes P J. Small airways in COPD.  N Engl J Med. 2004;  26 2635-2637
• 7 Gan W Q, Man S PF, Senthilselvan Aet al . Association between chronic obstructive pulmonary disease and systemic inflammation: a systemic review and a metaanalysis.  Thorax. 2004;  59 574-580
• 8 Schols A W, Soeters P J, Dingemans A MCet al . Prevalence and characteristics of nutritional depletion in patients with stable COPD eligible for pulmonary rehabilitation.  Am Rev Respir Dis. 1993;  147 1151-1156
• 9 Schols A W, Slangen J, Volovics Let al . Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease.  Am J Respir Crit CareMed. 1998;  157 1791-1797
• 10 Debigare R, Marquis K, Coté C Het al . Cataboloc/anabolic balance and muscle wasting in patients with COPD.  Chest. 2003;  124 83-89
• 11 Schols A M. Nutrition in chronic obstructive pulmonary disease.  Curr Opin Pulm Med. 2000;  6 110-115
• 12 Eid A A, Ionescu A A, Nixon L S. et al . Inflammatory response and body composition in chronic obstructive pulmonary disease.  Am J Respir Crit Care Med. 2001;  164 1414-1418
• 13 Cohen R I, Marzouk K, Berkosko P. et al . Body composition and resting energy expenditure in clinically stable, non-weight-losing patients with severe emphysema.  Chest. 2003;  124 1365-1372
• 14 John M, Hörnig S, Witt C. et al . Anemia and inflammation in chronic obstructive pulmonary disease.  Chest. 2005;  127 825-829
• 15 John M, Lange A, Hörnig S. et al . Prevalence of anemia in Chronic Obstructive Pulmonary Disease:Comparison to other chronic diseases.  Int J Cardiol. 2005;  im Druck
• 16 Agusti A GN. COPD, a muliticomponent disease: implications for management. Respir Med. Doi: 10.1016/j.rmed.2004.11.006
• 17 Celli B R, Cote C G, Marin J M. et al . The body mass index, airflow obstruction, dyspnoea, and exercise capacity index in chronic obstructive pulmonary disease.  N Engl J Med. 2004;  350 1005-1012
• 18 www.goldcopd.com. 
• 19 Calverley P, Pauwels R, Vestbo J. Combined salmeterol and fluticasone in treatment of chronic obstructive pulmonary disease: a randomised controlled trial.  Lancet. 2003;  361 449-456
• 20 Szafranski W, Cukier A, Ramirez A. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease.  Eur Respir J. 2003;  21 74-81
• 21 Calverley P M, Boonsawat W, Cseke Z. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease.  Eur Respir J. 2003;  22 912-919
• 22 O'Donnell D E, Flüge T, Gerken F. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD.  Eur Respir J. 2004;  23 832-840
• 23 O'Donnell D E, Voduc N, Fitzpatrick M. Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease.  Eur Respir J. 2004;  24 86-94
• 24 Aliverti A, Rodger K, Dellaca R L. The effect of salbutamol on lung function and chest wall volumes at rest and during exercise in COPD.  Thorax. 2005;  60 916-924 Epub ahead of print
• 25 National Emphysema Treatment Trial Research Group . A randomised trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema.  N Engl J Med. 2003;  348 2059-2073
• 26 Burge S, Wedzicha J A. COPD exacerbations: definitions and classifications.  Eur Respir J. 2003;  41 46s-53s
• 27 Brunton S, Carmichael B P, Colgan R. Acute exacerbation of chronic bronchitis: a primary care consensus guideline.  Am J Manag Care. 2004;  10 689-696
• 28 Anthonisen N R, Connett J E, Murray R P. for the Lung Health Study Research Group . Smoking and lung function of Lung Health Study participants after 11 years.  Am J Respir Crit Care Med. 2002;  166 675-679
• 29 Long term domicilary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party.  Lancet. 1981;  1 681-686
• 30 Crockett A J, Cranston J M, Moss J R. Survival on long-term oxygen therapy in chronic airflow limitation: from evidence to outcomes in the routine clinical setting.  Intern Med J. 2001;  31 448-454
• 31 Sin D, Tu J. Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease.  Am J Respir Crit Care Med. 2001;  164 580-584
• 32 Soriano J B, Vestbo J, Pride N B. Survival in COPD patients after use of salmeterol and/or fluticasone propionate in general practice.  Eur Respir J. 2002;  20 819-825
• 33 Suissa S. Effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease: immortal time bias in observational studies.  Am J Respir Crit Care Med. 2003;  168 49-53
• 34 The TORCH study group . The TORCH survival study protocol.  Eur Respir J. 2004;  24 206-210
• 35 Man S FP, Sin D D. Inhaled corticosteroids in chronic obstructive pulmonary disease. Is there a clinical benefit?.  Drugs. 2005;  65 579-591
• 36 Sin D D, Lacy P, York E. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease.  Am J Respir Crit Care Med. 2004;  170 760-765
• 37 De Melo M N, Ernst P, Suissa S. Inhaled corticosteroids and the risk of a first exacerbation in COPD patients.  Eur Respir J. 2004;  23 692-697
• 38 Soto J F, Hanania N A. Selective phosphodiesterase-4 inhibitoprs in chronic obstructive lung disease.  Current Opinion in Pulmonary Medicine. 2005;  11 129-134
• 39 Creutzberg E C, Wouters E F, Mostert R. A role for anabolic steroids in the rehabilitation of patients with COPD?.  Chest. 2003;  124 1733-1742
• 40 Barnes P J, Hansel T T. Prospects for new drugs for chronic obstructive pulmonary disease.  Lancet. 2004;  364 985-996